Enabling a Robust AAV Upstream Platform

On-Demand Webinar

Enabling a Robust AAV Upstream Platform Using Next-Generation Raw Materials

In collaboration with Nantes University, this webinar will demonstrate an upstream AAV platform made with a DOE approach. It achieved 70-fold increase in viral genome and 7-fold increase in full/empty capsid ratio compared to the initial process.

What You Will Learn:

Optimize process parameters using a DOE approach in a scale-down model.
Understand the impact of feeding strategies on AAV production.
Enhance transfection with a next-generation transfection reagent and helper plasmid.

Clear form data

Please Complete the Form

First Name *

Last Name *

E-Mail *

Phone Number *

Company *

Job Title *

Address *

Country *

Postal Code *

I would like to sign up for newsletters from Sartorius (Sartorius AG and its affiliated companies) based of my personal interests.
I can revoke my consent at any time with effect for the future by sending an e-mail to unsubscribe@sartorius.com or by clicking on the "unsubscribe" link in e-mails I have received.

* These fields are required Information on the use of your data can be found in our privacy policy

Complete Form to Watch

David Ede

Process Technology Manager

David is a biomedical and chemical engineer and has a background in process development and manufacturing for viral vectors.

In his current role as Process Technology Manager at Sartorius, David supports viral-based biotechnology stakeholders and helps bring their bioprocess from R&D to commercial scale.

Oumeya (Mia) Adjali, MD, PhD

Senior Scientist, Director of TaRGeT laboratory

Oumeya is an INSERM senior scientist and head of the Translational Research in Gene Therapy laboratory at Nantes University. She has worked at the interface of cell and gene therapies using lentiviral and AAV vectors for more than 22 years, and currently focuses on developing AAV gene therapy products from bench to bedside. She is vice president of the French Society of Cell and Gene Therapy.

Christophe Chevé, MSc

Bioprocess Scientist, TaRGeT

Christophe joined the Translational Research in Gene Therapy laboratory in 2006, focusing on cell line development for rAAV production. He now focuses on developing a scalable production platform using suspension-adapted HEK293 cells and a transient transfection system leveraging Ambr^® 15. He graduated from University of Nantes with a master’s degree in advanced therapy medicinal products.